Purpose: To evaluate the expression of tumor PD-L1 and changes in tumor-infiltrating lymphocyte (TIL) populations in metastatic melanoma patients treated with targeted MAPK inhibitors.
Introduction
Drugs inhibiting CTLA-4 on T-cells (ipilimumab) (1), or the mitogen-activated protein kinase (MAPK) pathway in BRAF mutant melanoma (vemurafenib, dabrafenib, cobimetinib and trametinib) have significantly improved the overall survival (OS) of patients with metastatic melanoma (2) (3) (4) (5) . Further improvements in patient outcomes have been achieved by monoclonal antibodies (MAb) that target the programmed cell death receptor 1 (PD-1, CD279) (6, 7) . PD-1 is expressed on a subset of activated T-cells, as well as other immune cells (8, 9) . Interaction of PD-1 on T-cells with its ligands programmed cell death ligand 1 (PD-L1, CD274) (10, 11) and programmed cell death ligand 2 (PD-L2, CD273) (12, 13) negatively regulates antigen receptor signaling and inhibits immune responses. PD-L1 is constitutively expressed on subsets of T-cells, B-cells, macrophages and dendritic cells (DCs). It may be further up regulated by cytokines such as interferon gamma (IFN-γ) released by CD4+ helper T-cells (14) , which is believed to result in feedback suppression and evasion of immune responses against the tumor (15, 16) .
Results from the phase 1 clinical trials of the anti-PD-1 antibodies nivolumab (6) and pembrolizumab (MK3475) (7) showed response rates of 28% and 38%, respectively in patients with advanced stage metastatic melanoma. Longer follow up on patients in phase 1 studies treated with nivolumab has shown 1 and 2 year survivals of 62% and 48%, respectively (17) , and 1 year survival in patients treated with pembrolizumab of 69% (65% in ipilimumab refractory patients and 74% in ipilimumab naïve patients) (18) . Higher response rates and survivals were reported in the results of the phase 1 study of the combination of nivolumab and ipilimumab in metastatic melanoma patients (19) . Phase 1 studies with monoclonal antibodies against PD-L1 have also shown promising results with minimal toxicities (20) . It is unknown whether there is potential for converting a subset of these patients, who fail either immunotherapy or targeted therapy alone into long-term responders by treating with PD-1/PD-L1 inhibitors in conjunction with MAPK targeted therapies. Furthermore, it is unclear whether immunotherapies such as PD-1/PD-L1 inhibitors would be best combined sequentially or concurrently with MAPK inhibitors. Recent studies in mouse models showed an enhanced response and prolonged survival using concurrent PD-1/PD-L1 and BRAF inhibition than either drug alone, as well as an increased T-cell infiltrate early during treatment (21) .
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Author Manuscript Published OnlineFirst on January 21, 2015; DOI: 10.1158/1078-0432.CCR- We have previously demonstrated that there is an increase in intratumoral CD4+ and CD8+ infiltrating lymphocytes early during treatment (EDT) in patients responding to BRAF inhibitors (22) . Early evidence from preclinical (23) and in-vivo (24) studies have suggested that there is an increase in PD-L1 expression in on-treatment biopsies with BRAFi and Combi, but this was performed only in a limited number of human melanoma tissue samples. It has also recently been shown that a higher density of peritumoral CD8+ lymphocytes at baseline is predictive of response in patients treated with PD-1 inhibitors (25), suggesting there could be possible synergy between targeted MAPK and checkpoint inhibitors. In this study, we sought to systemically assess the expression of PD-L1 on the tumor cell membrane as well as changes in immune markers on tumorinfiltrating lymphocytes (TILs) prior to treatment (PRE), EDT and on disease progression (PROG) in a large cohort of patients treated with single agent BRAF inhibitors vemurafenib or dabrafenib, or the combination of BRAF and MEK inhibitors dabrafenib and trametinib.
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Materials and Methods

Study design
Multiple tumor samples were collected from 40 patients with BRAF mutant unresectable AJCC stage III or stage IV melanoma during the course of their treatment with either a BRAF inhibitor alone (vemurafenib or dabrafenib) [BRAFi] or the combination of BRAF and MEK inhibitor (dabrafenib and trametinib) [Combi] as part of clinical trials accrued between 2009 and 2013. The BRAF mutation status was determined as previously described (26, 27) . The dosages and durations of treatment are described in Table 1 . A subset of patients included in this study have been previously reported but in all the cases each biopsy was reanalyzed for the purposes of this study (22) . Biopsied tumor specimens were collected from consenting patients prior to MAPK inhibitor treatment (PRE), early during treatment with MAPK inhibitor (EDT), and at disease progression (PROG), with Human Ethics Review Committee approval as part of the Treat Excise Analyze for Melanoma (TEAM) study at Melanoma Institute Australia. Clinical and follow-up details were collated and analyzed on all patients (Table 1 ). The size of the excised EDT tumor was measured with calipers prior to and early during treatment with MAPK inhibitor therapy, and the percentage change in area (short x long axis) was calculated. Computed tomographic (CT) scanning was carried out at 6-9 weekly intervals and response was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (28) . Progression-free survival (PFS) and overall survival were calculated from date of starting MAPK inhibitor to event (either progression or death) or until last follow up (censored).
Assessment of Tumor Infiltrating Lymphocytes
Patient biopsies were fixed with 10% buffered formalin solution and processed into paraffinembedded (FFPE) tissue blocks. Sections were cut from the FFPE blocks and hematoxylin and eosin (H&E) staining was performed. The density and distribution of TILs at both the tumor periphery and within the tumor were scored using a four-tiered system, as previously described (22) . The percentage of the tumor which had an infiltrate of lymphocytes was scored and the average number of lymphocytes per high power field (HPF) in a minimum of 4 representative HPF areas was given a semi-quantitative score using a four tiered scale (0= no lymphocytes, 1= 1-10/HPF, 2= 11-50/HPF and 3= >50/HPF). A TILs grade was derived by multiplying the percentage of tumor which had an infiltrate by the scores for the average number of lymphocytes per HPF to attain a score from 0-300. Diffuse (≥40% tumor PD-L1) staining associated with a proportionate TILs infiltrate ( Figure 1C) and pattern 4) Focal (<40% tumor PD-L1) staining associated with a proportionate TILs infiltrate either at the periphery of the tumor (pattern 4A) ( Figure 1D ) or non-peripherally within the tumor (pattern 4B) ( Figure 1E -F). In cases displaying more than one pattern, the predominant pattern was described. A subset of tumor samples deemed to be indeterminable for PD-L1 expression due to heavy melanin pigmentation were bleached for 24 hours with 10% H 2 O 2 prior to PD-L1 staining.
All slides were reviewed independently by at least two of three observers (HK, RV and RAS) who were blinded to clinical outcomes. Any discrepancies were resolved by consensus following review at a multi-header microscope.
Statistical analysis
Statistical analyses were conducted with "PASW Statistics 21" SPSS, IBM. Wilcoxon matchedpairs method was used to test for significant changes in immune markers between the different biopsy time points (PRE, EDT and PROG). Correlations between different immune markers were conducted using the Spearman's rho test. Univariate survival analysis was carried out using the Kaplan-Meier method together with the log-rank (Mantel-Cox) test to calculate statistical significance. Cox regression analysis was used to generate univariate hazard ratios (HRs), 95% confidence intervals (95% CI), and corresponding p values. Statistical significance was defined as a probability level < 0.05. 
Results
Patients' treatments and biopsies
Multiple tumor excision biopsies were available for analysis from 40 patients (Table 1) . All patients had a PRE biopsy prior to initiating MAPK inhibitor therapy and 28 had paired EDT biopsies and 25 PROG biopsies. There were 28 patients (28 PRE, 18 EDT, 18 PROG) treated with a BRAFi (dabrafenib=22 or vemurafenib=6) and 12 patients (12 PRE, 10 EDT, 7 PROG) treated with Combi (dabrafenib and trametinib). There were no significant differences in clinical features (i.e. age, sex, V600E/K mutation status, M stage, ECOG and LDH) at baseline between these two cohorts ( Table   1 ). All patients were immunotherapy naïve and 38 were MAPK inhibitor naïve at baseline (patient 34 and 35 had received a BRAF inhibitor prior to Combi). Twenty-eight (70%) patients had a BRAF V600E mutation and 12 (30%) had a BRAF V600K mutation. There were 14 females and 26 males and the median patient age was 51 years (range 23-80 years). Two patients achieved a complete response (CR), 25 had a partial response (PR), 12 had stable disease (SD) and one had progressive disease (PD) as their best RECIST response. The median follow-up period was 11 months (range 2-50 months), with a median time to progression of 5.5 months (range 1-15 months). At last follow up, 29 patients had died of melanoma and 11 patients were still alive. Of those still alive four had not progressed on MAPK inhibitor therapy.
PD-L1 expression on melanoma and immune cells
PD-L1 expression showed marked intratumoral and intertumoral heterogeneity both in the percentage of positive staining melanoma cells and the intensity of staining. Similar heterogeneity of PD-L1 staining was also observed on lymphocytes and macrophages (Supplementary Table 2 ). In the total cohort of 93 tumor samples taken at different time points, 55 (59%) displayed tumor immuno-reactivity for PD-L1 (Supplementary Table 2 positive biopsies, the median PD-L1 IRS was 5. Four (7.3%) cases showed diffuse (≥40% tumor PD-L1) staining that was unassociated with a proportionate TILs infiltrate (pattern 1), 1 ( 
Effect of MAPK inhibitors on PD-L1 expression
There was no significant difference in the overall tumor PD-L1 IRS or positivity rates between the different treatment time points (PRE, EDT and PROG). Positive tumor PD-L1 expression was identified in 24 of 40 (60%) PRE biopsies, 15 of 28 (54%) EDT biopsies and 16 of 25 (64%) PROG biopsies. There were no significant differences in staining patterns between the PRE, EDT and PROG time points; however the predominant pattern of staining in the biopsies was non-peripheral (intratumoral) focal PD-L1 positivity associated with a proportionate TILs infiltrate (pattern 4B) (Supplementary Table 1 ).
There was no significant change in lymphocyte or macrophage PD-L1 expression between the various time points and treatment regimens (Supplementary Table 2 ). Overall, there was no significant change in tumor PD-L1 expression from PRE to EDT in patients' tumors whether they were PD-L1 positive (n=20) or negative (n=8) at baseline. However, additional patient subgroups further defined by change in PD-L1, TILs, PD1+ lymphocytes from PRE to EDT were also examined in an attempt to identify associations with clinical outcome measures (see below) (Supplementary Figure 1) . There was no significant change in PD-L1 expression from PRE to PROG. However, in patients with PD-L1 positive tumors at baseline that had a matched PROG sample (n=13), PD-L1 expression significantly decreased from PRE to PROG (p=0.028) ( Figure   2A ). This coincided with a significant decrease in TILs (p=0.035) from PRE to PROG. In contrast, PD-L1 expression increased significantly from PRE to PROG (p=0.008) ( Figure 2B ) in those with PD-L1 negative tumors at baseline that had a matched PROG sample (n=12). This coincided with a significant increase in TILs (p=0.008) and PD-1+ lymphocytes (p=0.044) from PRE to PROG.
BRAF inhibitor monotherapy and combination MAPK inhibitor therapy had similar effects on TIL influx in sequential biopsies
In the total cohort of patients (n=40), there was a significant increase in TILs from PRE to EDT (p=0.000063), which then decreased significantly from EDT to PROG (p=0.045). There was no significant difference in TILs between the PRE and PROG biopsies (p=0.594). There was a significant increase in the CD4+, CD8+ and PD-1+ intratumoral lymphocyte subsets (p=0.00004, p=0.00003, p=0.007, respectively) from PRE to EDT. However, the decreases from EDT to PROG in these markers were not significant. There was no significant change in FOXP3+ regulatory T Figure 2) , with levels of expression being variable at PRE, EDT and PROG in different patients. There was also no significant change in CD68 expressing macrophages at any time point in either the BRAFi treated or Combi treated patients. In patients treated with Combi, there were significant increases in CD4+ and CD8+ intratumoral lymphocytes from PRE to EDT (p=0.011 and p=0.013, respectively) ( Figure 3D & E) , which were similar to the increases seen in patients treated with BRAFi (p=0.001 and p=0.001, respectively) ( Figure 3A & B) . However, there was a significant increase in PD-1+ intratumoral lymphocytes from PRE to EDT in patients treated with BRAFi (p=0.017) ( Figure 3C) that did not reach significance in the biopsies of patients treated with Combi (p=0.205) ( Figure 3F ).
In patients samples with the BRAF V600K mutation (n=12, 8 treated with BRAFi and 4 with Combi), there were significant increases in PD-1+ and LAG3+ lymphocytes from PRE to EDT (p=0.035 and p=0.028, respectively), which was not seen in the samples from patients with the BRAF V600E mutation (n=28).
Clinical outcome, T cell correlates and PD-L1 expression
The expression of the immune markers CD4, CD8, PD1, LAG3 and FOXP3 in lymphocytes and tumor PD-L1 IRS scores at any time point as well as the changes from PRE to EDT, PRE to PROG and EDT to PROG did not show any significant correlation with any clinical parameters such as site of PRE biopsy, best RECIST response, EDT tumor response, number of days to the EDT biopsy, change in the EDT tumor size, PFS and OS. In contrast, increased TILs at PRE biopsy was associated with a better RECIST response (p=0.002), but not improved PFS or OS.
Analysis based on patients' PD-L1 status at baseline and the change in PD-L1, TILs, and PD-1+ lymphocytes from PRE to EDT, revealed subgroups with marked heterogeneity in response to Discussion PD-L1 expression on melanoma cells is believed to be induced mainly by T cell responses mounted against the tumor and to be an important adaptive response that allows escape from immune attack (35, 36) . In some melanomas, PD-L1 expression may also be driven through oncogenic pathways as has been described in non-small cell lung carcinoma with EGFR mutations (37) in PD-L1 expression and an increase in TILs and PD-1+ lymphocytes from baseline to early during treatment. This may indicate a decreased ability of the melanoma cells to inhibit the effect of the differentiated PD-1+ lymphocytes through binding with PD-L1, thereby prolonging the latter's cytotoxic activity.
Our findings extend those of Frederick and colleagues who assessed, in a smaller cohort of patients (n=11), the mRNA levels of PD-L1 in fresh frozen tumors taken at baseline, early-during treatment and at progression in patients receiving MAPK inhibitors and validated their findings using IHC in matched patients' samples (24) . They showed a significantly increased level of the transcript in patients' early-during treatment biopsies compared to baseline biopsies. In our study, we utilized the highly specific PD-L1 antibody (22C3) to clearly detect the clinically relevant (39) membranous staining on the tumor cells. Whereas Frederick et al showed a significant increase in PD-L1 from baseline to early during treatment, which remained high in the progressed lesion, in our study there were distinct subsets of patients which showed differential expression of PD-L1 in their biopsies. The inclusion of patients in this study that had been treated with both dabrafenib and trametinib provided us an opportunity to determine whether differences in PD-L1 expression and TILs might contribute to the improved PFS and OS seen in patients treated with the combination compared to those treated with dabrafenib alone. This was particularly important as previous studies have shown that MEK inhibitors are potentially immunosuppressive (40, 41) . We found no evidence for marked immunosuppressive effects in the TILs in the sequential biopsies taken from patients treated with Combi, which appeared comparable to those in patients treated with BRAFi monotherapy. A significant increase in PD-1+ lymphocytes at EDT was observed in patients treated with BRAFi alone but not in the Combi treated group. PD-1 expression on lymphocytes is a mechanism of early terminal differentiation and our results could indicate a potential defect in the differentiation of Tcells in the Combi treated patients. Alternatively, it could be that there was a lack of power in our study to identify significant differences in PD-1 expressing lymphocytes as there were fewer Combi treated patients (n=12) compared to patients treated with BRAFi alone (n=28). LAG3, another checkpoint inhibitor, is believed to reflect decreased effector T-cell function as a result of activation of the egr2 transcription factor (42) . Interestingly, we observed no substantial differences in LAG3 expressing T-cells in patients treated with BRAFi or Combi. Activation of the MAPK pathway is known to be strongly immunosuppressive (43) and its reactivation is a common mechanism for failure of treatment with BRAFi (38, 44) . Induction of suppressor T-cells has also been implicated as a cause of tumor progression but we did not detect significant changes in FOXP3+ lymphocytes at any time point with either BRAFi or Combi.
In conclusion, our data showing the addition of MEKi to BRAFi did not result in significant reduction in immune-infiltration of CD4+ and CD8+ lymphocytes into the early during treatment biopsies, which taken together with the results of a recent study demonstrating the predictive value of baseline peritumoral CD8+ lymphocytes for response to PD-1 inhibitors (25) patients that had a negative PD-L1 IRS at baseline had a significant increase at time of progression (n=12). * significance taken at p<0.05. 
